Myriad Genetics annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Myriad Genetics Revenue Growth & History (MYGN)
Myriad Genetics reported $824.5M in revenue for fiscal 2025, a decrease of 1.56% from the previous fiscal year.
View full Myriad Genetics company overviewMyriad Genetics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $824.5M | −$13.1M | −1.56% |
| 2024 | 2024-12-31 | $837.6M | $84.4M | +11.21% |
| 2023 | 2023-12-31 | $753.2M | $74.8M | +11.03% |
| 2022 | 2022-12-31 | $678.4M | −$12.2M | −1.77% |
| 2021 | 2021-12-31 | $690.6M | $133.5M | +23.96% |
| 2020 · Dec 31 | 2020-12-31 | $557.1M | — | — |
| 2020 · Jun 30 | 2020-06-30 | $638.6M | −$212.5M | −24.97% |
| 2019 | 2019-06-30 | $851.1M | $107.4M | +14.44% |
| 2018 | 2018-06-30 | $743.7M | $15.0M | +2.06% |
| 2017 | 2017-06-30 | $728.7M | −$11.8M | −1.59% |
| 2016 | 2016-06-30 | $740.5M | $18.0M | +2.49% |
| 2015 | 2015-06-30 | $722.5M | −$55.7M | −7.16% |
| 2014 | 2014-06-30 | $778.2M | $165.0M | +26.91% |
| 2013 | 2013-06-30 | $613.2M | $117.2M | +23.63% |
| 2012 | 2012-06-30 | $496.0M | $93.9M | +23.36% |
| 2011 | 2011-06-30 | $402.1M | $39.4M | +10.87% |
| 2010 | 2010-06-30 | $362.6M | $36.1M | +11.06% |
| 2009 | 2009-06-30 | $326.5M | — | — |
Myriad Genetics quarterly revenue
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $190.7M | −$22.4M | −10.51% |
| Q1 2026 | 2026-03-31 | $200.4M | $4.5M | +2.30% |
| Q4 2025 | 2025-12-31 | $209.8M | −$800,000 | −0.38% |
| Q3 2025 | 2025-09-30 | $205.7M | −$7.6M | −3.56% |
| Q2 2025 | 2025-06-30 | $213.1M | $1.6M | +0.76% |
| Q1 2025 | 2025-03-31 | $195.9M | −$6.3M | −3.12% |
| Q4 2024 | 2024-12-31 | $210.6M | $14.0M | +7.12% |
| Q3 2024 | 2024-09-30 | $213.3M | $21.4M | +11.15% |
| Q2 2024 | 2024-06-30 | $211.5M | $28.0M | +15.26% |
| Q1 2024 | 2024-03-31 | $202.2M | $21.0M | +11.59% |
| Q4 2023 | 2023-12-31 | $196.6M | $18.8M | +10.57% |
| Q3 2023 | 2023-09-30 | $191.9M | $35.5M | +22.70% |
| Q2 2023 | 2023-06-30 | $183.5M | $4.2M | +2.34% |
| Q1 2023 | 2023-03-31 | $181.2M | $16.3M | +9.88% |
| Q4 2022 | 2022-12-31 | $177.8M | $17.0M | +10.57% |
| Q3 2022 | 2022-09-30 | $156.4M | −$10.9M | −6.52% |
| Q2 2022 | 2022-06-30 | $179.3M | −$10.1M | −5.33% |
| Q1 2022 | 2022-03-31 | $164.9M | −$8.2M | −4.74% |
| Q4 2021 | 2021-12-31 | $160.8M | $6.2M | +4.01% |
| Q3 2021 | 2021-09-30 | $167.3M | $22.1M | +15.22% |
| Q2 2021 | 2021-06-30 | $189.4M | $96.2M | +103.22% |
| Q1 2021 · Mar 31 | 2021-03-31 | $173.1M | $9.1M | +5.55% |
| Q4 2020 · Dec 31 | 2020-12-31 | $154.6M | −$40.5M | −20.76% |
| Q1 2021 · Sep 30 | 2020-09-30 | $145.2M | −$41.1M | −22.06% |
| Q4 2020 · Jun 30 | 2020-06-30 | $93.2M | −$122.2M | −56.73% |
| Q3 2020 | 2020-03-31 | $164.0M | −$52.6M | −24.28% |
| Q2 2020 | 2019-12-31 | $195.1M | −$21.7M | −10.01% |
| Q1 2020 | 2019-09-30 | $186.3M | −$16.0M | −7.91% |
| Q4 2019 | 2019-06-30 | $215.4M | $21.5M | +11.09% |
| Q3 2019 | 2019-03-31 | $216.6M | $33.5M | +18.30% |
| Q2 2019 | 2018-12-31 | $216.8M | $28.9M | +15.38% |
| Q1 2019 | 2018-09-30 | $202.3M | $23.5M | +13.14% |
| Q4 2018 | 2018-06-30 | $193.9M | −$5.7M | −2.86% |
| Q3 2018 | 2018-03-31 | $183.1M | −$11.6M | −5.96% |
| Q2 2018 | 2017-12-31 | $187.9M | −$8.8M | −4.47% |
| Q1 2018 | 2017-09-30 | $178.8M | −$100,000 | −0.06% |
| Q4 2017 | 2017-06-30 | $199.6M | $26.4M | +15.24% |
| Q3 2017 | 2017-03-31 | $194.7M | $4.2M | +2.20% |
| Q2 2017 | 2016-12-31 | $196.7M | $3.4M | +1.76% |
| Q1 2017 | 2016-09-30 | $178.9M | −$4.6M | −2.51% |
| Q4 2016 | 2016-06-30 | $173.2M | −$16.1M | −8.51% |
| Q3 2016 | 2016-03-31 | $190.5M | $10.5M | +5.83% |
| Q2 2016 | 2015-12-31 | $193.3M | $8.9M | +4.83% |
| Q1 2016 | 2015-09-30 | $183.5M | $14.7M | +8.71% |
| Q4 2015 | 2015-06-30 | $189.3M | $551,000 | +0.29% |
| Q3 2015 | 2015-03-31 | $180.0M | −$2.9M | −1.60% |
| Q2 2015 | 2014-12-31 | $184.4M | −$19.7M | −9.63% |
| Q1 2015 | 2014-09-30 | $168.8M | −$33.7M | −16.63% |
| Q4 2014 | 2014-06-30 | $188.7M | $14.6M | +8.38% |
| Q3 2014 | 2014-03-31 | $182.9M | $26.5M | +16.91% |
| Q2 2014 | 2013-12-31 | $204.1M | $54.9M | +36.82% |
| Q1 2014 | 2013-09-30 | $202.5M | $69.0M | +51.73% |
| Q4 2013 | 2013-06-30 | $174.2M | $41.2M | +30.98% |
| Q3 2013 | 2013-03-31 | $156.5M | $26.7M | +20.57% |
| Q2 2013 | 2012-12-31 | $149.1M | $26.3M | +21.44% |
| Q1 2013 | 2012-09-30 | $133.4M | $23.0M | +20.81% |
| Q4 2012 | 2012-06-30 | $133.0M | $25.6M | +23.79% |
| Q3 2012 | 2012-03-31 | $129.8M | $27.4M | +26.77% |
| Q2 2012 | 2011-12-31 | $122.8M | $22.4M | +22.27% |
| Q1 2012 | 2011-09-30 | $110.5M | $18.6M | +20.24% |
| Q4 2011 | 2011-06-30 | $107.4M | $13.5M | +14.36% |
| Q3 2011 | 2011-03-31 | $102.4M | $11.5M | +12.71% |
| Q2 2011 | 2010-12-31 | $100.4M | $7.7M | +8.27% |
| Q1 2011 | 2010-09-30 | $91.9M | $6.7M | +7.91% |
| Q4 2010 | 2010-06-30 | $93.9M | — | — |
| Q3 2010 | 2010-03-31 | $90.8M | — | — |
| Q2 2010 | 2009-12-31 | $92.8M | — | — |
| Q1 2010 | 2009-09-30 | $85.1M | — | — |
Myriad Genetics revenue growth trends
Over the last five reported fiscal years, revenue grew from $557.1M to $824.5M, a compound annual growth rate of 8.16%. Myriad Genetics's latest reported quarter, Q2 2026, generated $190.7M in revenue, a decrease of 10.51% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Myriad Genetics source filings ↗